Development of an oncolytic herpes simplex virus using a tumor-specific HIF-responsive promoter

Cancer Gene Therapy

Volumn 18, Issue 2, 2011, Pages 123-134

  Longo, S L ^a   Griffith, C ^a   Glass, A ^a   Shillitoe, E J ^a   Post, D E ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

herpes simplex virus; HSV; hypoxia; hypoxia inducible factor (HIF); ICP4; oncolytic

Indexed keywords

ACICLOVIR; HYPOXIA INDUCIBLE FACTOR; NUCLEIC ACID BINDING PROTEIN; ONCOLYTIC HERPES SIMPLEX VIRUS TYPE 1; ONCOLYTIC HERPES VIRUS; RECOMBINANT PROTEIN; THYMIDINE KINASE; TUMOR PROMOTER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CONTROLLED STUDY; CYTOLYSIS; GENE; GENE DELETION; GENE EXPRESSION; GENE LOCUS; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; HYPOXIA; INFECTED CELL POLYPEPTIDE 4 GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR CELL; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; GENE DELETION; GENE EXPRESSION REGULATION, VIRAL; GLIOMA; HERPESVIRUS 1, HUMAN; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IMMEDIATE-EARLY PROTEINS; ONCOLYTIC VIRUSES; PROMOTER REGIONS, GENETIC; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; VERO CELLS; VIRUS REPLICATION;

HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 78751631362     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.62     Document Type: Article

References (50)

1. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5835.
2. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macro-phages. Am J Pathol 2000; 157: 411-421.
3. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009; 15: 501-513.
4. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008; 15: 678-685.
5. Brown JM. Tumor hypoxia in cancer therapy. Methods Enzymol 2007; 435: 297-321.
6. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007; 12: 853-859.
7. Bardos JI, Ashcroft M. Negative and positive regulation of HIF-1: a complex network. Biochim Biophys Acta 2005; 1755: 107-120.
8. Grandi P, Peruzzi P, Reinhart B, Cohen JB, Chiocca EA, Glorioso JC. Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Rev Neurother 2009; 9: 505-517.
9. Friedman GK, Pressey JG, Reddy AT, Markert JM, Gillespie GY. Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther 2009; 17: 1125-1135.
10. Hardcastle J, Kurozumi K, Chiocca EA, Kaur B. Oncolytic viruses driven by tumor-specific promoters. Curr Cancer Drug Targets 2007; 7: 181-189.
11. DeLuca NA, McCarthy AM, Schaffer PA. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol 1985; 56: 558-570.
12. Miyatake S, Iyer A, Martuza RL, Rabkin SD. Transcrip-tional targeting of herpes simplex virus for cell-specific replication. J Virol 1997; 71: 5124-5132.
13. Miyatake SI, Tani S, Feigenbaum F, Sundaresan P, Toda H, Narumi O et al. Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther 1999; 6: 564-572.
14. Yamamura H, Hashio M, Noguchi M, Sugenoya Y, Osakada M, Hirano N et al. Identification of the transcrip-tional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res 2001; 61: 3969-3977.
15. Kuroda T, Rabkin SD, Martuza RL. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res 2006; 66: 10127-10135.
16. Mullen JT, Kasuya H, Yoon SS, Carroll NM, Pawlik TM, Chandrasekhar S et al. Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Ann Surg 2002; 236: 502-512.
17. Griffith C, Noonan S, Lou E, Shillitoe EJ. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16. Cancer Gene Ther 2007; 14: 985-993.
18. Post DE, Van Meir EG. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther 2001; 8: 1801-1807.
19. ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999; 9: 469-479.
20. Post DE, Devi NS, Li Z, Brat DJ, Kaur B, Nicholson A et al. Cancer therapy with a replicating oncolytic adenovirus 1 targeting the hypoxic microenvironment of tumors. Clin Cancer Res 2004; 10: 8603-8612.
21. Smith CA, Schaffer PA. Mutants defective in herpes simplex virus type 2 ICP4: isolation and preliminary characterization. J Virol 1987; 61: 1092-1097.
22. Post DE, Van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 2003; 22: 2065-2072.
23. Su YH, Zhang X, Wang X, Fraser NW, Block TM. Evidence that the immediate-early gene product ICP4 is necessary for the genome of the herpes simplex virus type 1 ICP4 deletion mutant strain d120 to circularize in infected cells. J Virol 2006; 80: 11589-11597.
24. Post DE, Sandberg EM, Kyle MM, Devi NS, Brat DJ, Xu Z et al. Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with inter-leukin-4. Cancer Res 2007; 67: 6872-6881.
25. Cherry T, Longo SL, Tovar-Spinoza Z, Post DE. Second-generation HIF-activated oncolytic adenoviruses with improved repliction, oncolytic, and anti-tumor efficacy. Gene Ther 2010; e-pub ahead of print 22 July 2010, doi:10.1038/gt.2010.100.
26. Zinkernagel AS, Johnson RS, Nizet V. Hypoxia inducible factor (HIF) function in innate immunity and infection. J Mol Med 2007; 85: 1339-1346.
27. Wakisaka N, Kondo S, Yoshizaki T, Murono S, Furukawa M, Pagano JS. Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha. Mol Cell Biol 2004; 24: 5223-5234.
28. Kondo S, Seo SY, Yoshizaki T, Wakisaka N, Furukawa M, Joab I et al. EBV latent membrane protein 1 up-regulates hypoxia-inducible factor 1alpha through Siah1-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasophar-yngeal epithelial cells. Cancer Res 2006; 66: 9870-9877.
29. Carroll PA, Kenerson HL, Yeung RS, Lagunoff M. Latent Kaposi's sarcoma-associated herpesvirus infection of en-dothelial cells activates hypoxia-induced factors. J Virol 2006; 80: 10802-10812.
30. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 2000; 60: 4873-4880.
31. Cai Q, Murakami M, Si H, Robertson ES. A potential alpha-helix motif in the amino terminus of LANA encoded by Kaposi's sarcoma-associated herpesvirus is critical for nuclear accumulation of HIF-1alpha in normoxia. J Virol 2007; 81: 10413-10423.
32. Cai Q, Lan K, Verma SC, Si H, Lin D, Robertson ES. Kaposi's sarcoma-associated herpesvirus latent protein LANA interacts with HIF-1 alpha to upregulate RTA expression during hypoxia: latency control under low oxygen conditions. J Virol 2006; 80: 7965-7975.
33. Shin YC, Joo CH, Gack MU, Lee HR, Jung JU. Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 3 stabilizes hypoxia-inducible factor-1 alpha to induce vascular endothelial growth factor expression. Cancer Res 2008; 68: 1751-1759.
34. Deshmane SL, Mukerjee R, Fan S, Del VL, Michiels C, Sweet T et al. Activation of the oxidative stress pathway by HIV-1 Vpr leads to induction of hypoxia-inducible factor 1alpha expression. J Biol Chem 2009; 284: 11364-11373.
35. Nasimuzzaman M, Waris G, Mikolon D, Stupack DG, Siddiqui A. Hepatitis C virus stabilizes hypoxia-inducible factor 1alpha and stimulates the synthesis of vascular endothelial growth factor. J Virol 2007; 81: 10249-10257.
36. Tomita M, Semenza GL, Michiels C, Matsuda T, Uchihara JN, Okudaira T et al. Activation of hypoxia-inducible factor 1 in human T-cell leukaemia virus type 1-infected cell lines and primary adult T-cell leukaemia cells. Biochem J 2007; 406: 317-323.
37. Yoo YG, Oh SH, Park ES, Cho H, Lee N, Park H et al. Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1alpha through activation of mitogen-activated protein kinase pathway. J Biol Chem 2003; 278: 39076-39084.
38. Yoo YG, Cho S, Park S, Lee MO. The carboxy-terminus of the hepatitis B virus X protein is necessary and sufficient for the activation of hypoxia-inducible factor-1alpha. FEBS Lett 2004; 577: 121-126.
39. Hagglund R, Roizman B. Role of ICP0 in the strategy of conquest of the host cell by herpes simplex virus 1. J Virol 2004; 78: 2169-2178.
40. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000; 14: 34-44.
41. Stoeltzing O, McCarty MF, Wey JS, Fan F, Liu W, Belcheva A et al. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst 2004; 96: 946-956.
42. Li L, Lin X, Staver M, Shoemaker A, Semizarov D, Fesik SW et al. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 2005; 65: 7249-7258.
43. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 2007; 67: 4157-4163.
44. Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007; 67: 563-572.
45. Kondo K, Kim WY, Lechpammer M, Kaelin Jr WG. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003; 1: E83.
46. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM et al. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 2000; 60: 4010-4015.
47. Blouw B, Song H, Tihan T, Bosze J, Ferrara N, Gerber HP et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003; 4: 133-146.
48. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogen-esis. Nature 1998; 394: 485-490.
49. Moon EJ, Jeong CH, Jeong JW, Kim KR, Yu DY, Murakami S et al. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha. FASEB J 2004; 18: 382-384.
50. Kurozumi K, Hardcastle J, Thakur R, Shroll J, Nowicki M, Otsuki A et al. Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther 2008; 16: 1382-1391.